Horizon scanning: Riociguat filed in the EU and US for pulmonary arterial hypertension

Source: PharmaTimes Area: News Bayer has submitted riociguat for filing in the US and EU as an oral  treatment for patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), a related condition.   The application is based on PAH data from the PATENT-I trial (see NELM abstract below) and data from the CHEST-1 study in CTEPH patients which reported similar improvements (no absolute data available for CHEST-1).
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news